Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Agenus stock in Canada

Own Agenus shares in just a few minutes.

Agenus is a biotechnology business based in the US. Agenus stocks (AGEN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.55 – a decrease of 5.28% over the previous week. Agenus employs 359 staff and has a trailing 12-month revenue of around $306.7 million.

How to buy shares in Agenus

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Agenus stock price (NASDAQ:AGEN)

Use our graph to track the performance of AGEN stocks over time.

Agenus shares at a glance

Information last updated 2022-01-23.
Latest market close$2.69
52-week range$2.44 - $6.79
50-day moving average $3.29
200-day moving average $4.47
Wall St. target price$10.00
PE ratio 148.8889
Dividend yield N/A (0%)
Earnings per share (TTM) $0.02

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Agenus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Agenus price performance over time

Historical closes compared with the close of $2.69 from 2022-01-24

1 week (2022-01-19) -4.27%
1 month (2021-12-23) -24.86%
3 months (2021-10-26) -29.02%
6 months (2021-07-26) -49.25%
1 year (2021-01-26) -27.40%
2 years (2020-01-24) -28.84%
3 years (2019-01-25) 3.5
5 years (2017-01-25) 3.76

Is Agenus under- or over-valued?

Valuing Agenus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Agenus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Agenus's P/E ratio

Agenus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 149x. In other words, Agenus shares trade at around 149x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Agenus's EBITDA

Agenus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $75.1 million.

The EBITDA is a measure of a Agenus's overall financial performance and is widely used to measure a its profitability.

Agenus financials

Revenue TTM $306.7 million
Operating margin TTM 22.23%
Gross profit TTM $-56,796,000
Return on assets TTM 13.27%
Return on equity TTM 0%
Profit margin 1.3%
Book value $0.17
Market capitalisation $688.3 million

TTM: trailing 12 months

Agenus share dividends

We're not expecting Agenus to pay a dividend over the next 12 months.

Have Agenus's shares ever split?

Agenus's shares were split on a 1:6 basis on 3 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.

Agenus share price volatility

Over the last 12 months, Agenus's shares have ranged in value from as little as $2.44 up to $6.79. A popular way to gauge a stock's volatility is its "beta".

AGEN.US volatility(beta: 1.13)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.1292. This would suggest that Agenus's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Agenus overview

Agenus Inc. , a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc.

Stocks similar to Agenus

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site